3 most recent filings and news items mentioning COCP. Updated every 60 seconds.
LeadershipJun 9, 2026Positive
Cocrystal Pharma announced the appointment of James Sapirstein as Chief Executive Officer effective June 3, 2026, with a $265,000 annual salary and 235,000 stock options. The leadership change signals organizational transition and provides equity incentive alignment with company
View filing at SEC.gov →
LeadershipJun 3, 2026Positive
Cocrystal Pharma appointed James Sapirstein as Chief Executive Officer effective immediately, replacing co-CEOs Sam Lee and Jim Martin. Sapirstein brings 23 product launches and extensive antiviral development experience from prior roles at Contravir, Tobira, and Gilead Sciences.
View filing at SEC.gov →
OtherMay 26, 2026Positive
Cocrystal Pharma announced discovery of novel direct-acting antivirals with pan-viral activity against hantavirus, bunyavirus and influenza, targeting a conserved viral replication enzyme region. The announcement addresses significant unmet medical needs for hantavirus and bunyav
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.